Company Overview of Visterra, Inc.
Visterra, Inc. operates as a biotechnology company. It uses its atomic interaction network analysis to identify disease targets and design therapeutics. The company focuses on therapeutics for infectious diseases and its antibody product candidate, VIS410, a human monoclonal antibody for the prevention and treatment of seasonal and pandemic influenza. It also develops dengue antibody programs; and has a drug development program for an antibody to treat four strains of dengue virus. In addition, it focuses on research programs for infectious and non-infectious diseases; and other collaborative programs. Visterra, Inc. was formerly known as Parasol Therapeutics, Inc. and changed its name to Vi...
One Kendall Square
Cambridge, MA 02139
Founded in 2007
Key Executives for Visterra, Inc.
Chief Executive Officer, President and Director
Chief Financial Officer and Chief Operating Officer
Vice President of Business Development and Strategic Planning
Compensation as of Fiscal Year 2015.
Visterra, Inc. Key Developments
Visterra Partners with Agency for Science, Technology and Research to Develop VIS513
May 21 15
Visterra, Inc. and the Drug Discovery & Development (D3) unit under the Agency for Science, Technology and Research, Singapore announced a collaboration to further the development of VIS513, Visterra's broadly neutralizing antibody for the treatment of dengue fever. VIS513, which was engineered using Visterra's innovative and proprietary technology, is a humanized monoclonal antibody that is designed to bind and potently neutralize all four serotypes of dengue virus. The company's preclinical studies of VIS513 in animal models have demonstrated a rapid reduction in viral titers after a single systemic administration, which supports its potential use as a single administration treatment for dengue virus infection. The collaboration combines Visterra's expertise in therapeutic antibodies for challenging infectious diseases with D3's proficiency in bringing early stage discoveries into clinical development. D3 and Visterra will also work together with infectious disease experts at Duke-National University of Singapore (Duke-NUS) to generate additional data necessary to initiate clinical trials of VIS513. Upon completion of these activities, D3 and Visterra will advance VIS513 through proof-of-concept clinical trials in humans, which will be conducted in Singapore. Under the terms of the collaboration agreement Visterra retains all rights to develop and commercialize VIS513 globally.
Visterra Announces Additions to its Management Team and Board of Directors
Oct 31 14
Visterra, Inc. announced two key additions to the company's executive management team and board of directors. José M. Trevejo, MD, PhD, has been appointed Vice President of Development and Akshay Vaishnaw, MD, PhD, of Alnylam Pharmaceuticals, Inc. has been elected to the company's board of directors. In his role as Vice President of Development, Dr. Trevejo will oversee all preclinical and clinical development, as well as regulatory affairs for the company. This includes advancing clinical programs for product candidates from Visterra's pipeline of novel monoclonal antibodies that target infectious diseases, including advancing VIS410 for seasonal and pandemic influenza into phase 2 clinical studies and progressing VIS513 for dengue fever into the clinic. Prior to joining Visterra, Dr. Trevejo served as Medical Director at Genentech, Inc. Dr. Vaishnaw is currently Executive Vice President and Chief Medical Officer of Alnylam Pharmaceuticals, Inc., which he joined in 2006.
Visterra, Inc. Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-16-2014 10:00 AM
Jan 10 14
Visterra, Inc. Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-16-2014 10:00 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States. Speakers: Brian J. G. Pereira, Chief Executive Officer, President and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
October 2, 2014